Anti-CCNL1/ ANIA6A/ BM-001 functional antibody
Anti-CCNL1/ ANIA6A/ BM-001 functional antibody for cell culture, ELISA & in-vivo assay
Go to CCNL1/CCNL1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-SE1562-Ab-1/ GM-Tg-hg-SE1562-Ab-2 | Anti-Human CCNL1 monoclonal antibody | Human |
GM-Tg-rg-SE1562-Ab-1/ GM-Tg-rg-SE1562-Ab-2 | Anti-Rat CCNL1 monoclonal antibody | Rat |
GM-Tg-mg-SE1562-Ab-1/ GM-Tg-mg-SE1562-Ab-2 | Anti-Mouse CCNL1 monoclonal antibody | Mouse |
GM-Tg-cynog-SE1562-Ab-1/ GM-Tg-cynog-SE1562-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CCNL1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-SE1562-Ab-1/ GM-Tg-felg-SE1562-Ab-2 | Anti-Feline CCNL1 monoclonal antibody | Feline |
GM-Tg-cang-SE1562-Ab-1/ GM-Tg-cang-SE1562-Ab-2 | Anti-Canine CCNL1 monoclonal antibody | Canine |
GM-Tg-bovg-SE1562-Ab-1/ GM-Tg-bovg-SE1562-Ab-2 | Anti-Bovine CCNL1 monoclonal antibody | Bovine |
GM-Tg-equg-SE1562-Ab-1/ GM-Tg-equg-SE1562-Ab-2 | Anti-Equine CCNL1 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-SE1562-Ab-1/ GM-Tg-hg-SE1562-Ab-2; GM-Tg-rg-SE1562-Ab-1/ GM-Tg-rg-SE1562-Ab-2; GM-Tg-mg-SE1562-Ab-1/ GM-Tg-mg-SE1562-Ab-2; GM-Tg-cynog-SE1562-Ab-1/ GM-Tg-cynog-SE1562-Ab-2; GM-Tg-felg-SE1562-Ab-1/ GM-Tg-felg-SE1562-Ab-2; GM-Tg-cang-SE1562-Ab-1/ GM-Tg-cang-SE1562-Ab-2; GM-Tg-bovg-SE1562-Ab-1/ GM-Tg-bovg-SE1562-Ab-2; GM-Tg-equg-SE1562-Ab-1/ GM-Tg-equg-SE1562-Ab-2 |
Products Name | Anti-CCNL1 monoclonal antibody |
Format | mab |
Target Name | CCNL1 |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-CCNL1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-SE1562-Ag-1 | Recombinant multi-species CCNL1/ ANIA6A/ BM-001 protein |
Target information
Target ID | GM-SE1562 |
Target Name | CCNL1 |
Gene ID | 57018,56706,114121,705208,111092016,101087775,514613,100050292 |
Gene Symbol and Synonyms | 2610030E23Rik,ania-6a,ANIA6A,BM-001,Ccnl,CCNL1,cyclin-L1,PRO1073 |
Uniprot Accession | Q9UK58,Q9R1Q2 |
Uniprot Entry Name | CCNL1_HUMAN,CCNL1_RAT |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000163660 |
Target Classification | N/A |
The target: CCNL1, gene name: CCNL1, also named as ANIA6A, BM-001, PRO1073, ania-6a. Predicted to enable cyclin-dependent protein serine/threonine kinase regulator activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Located in nucleus. [provided by Alliance of Genome Resources, Apr 2022].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.